Placeholder

Reform, Consolidation, and Good Citizenry

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1888. Categories: , .

Product Description

Digital Exclusive
Our experts featured in this issue identify healthcare reform, mergers and acquisitions, and corporate reputation as three of the many market changers that will impact how the industry does business in the future.

The year-long legislative endeavor to create a healthcare reform bill that all sides will agree upon took a step closer to reality as the latest version of the bill headed back to the floor for further discussion. The Senate Finance Committee’s version, which passed on Oct. 13, 2009, completely omits a public or government-run health insurance plan, and would spend $829 billion over the next decade to finance the expansion of Medicaid. It also sets out to provide federal subsidies to 18 million people who do not have coverage, extends health insurance coverage to an estimated 30 million Americans, and excludes an estimated 20 million illegal immigrants.
Our experts discuss the pros and cons of the proposed healthcare plans and how these may shape the market and how the industry…

Sidebar:
Global Risks Facing Life Sciences
Key Pricing and Financing ­Proposals

Access Demo Reputation Strategies That Drive Market Results: Turning Your Good Name into Good Business
Access Demo Improving the Industry’s Reputation

Experts on this topic
Joseph Baron. Partner, Extera Partners, which ­provides interim senior management, focused ­consulting, and selective financial investment to life-sciences companies. For more information, visit ­exterapartners.com.
Paul Boni. Chief Research Officer, Grail Research, a global research and decision support firm that ­provides organizations with answers to their most important business questions. For more information, visit grailresearch.com.
Carolyn Buck Luce. Global Pharmaceutical ­Leader of Ernst & Young, a global provider of ­assurance, tax, transaction, and advisory services. For more ­information, visit ey.com.
Sam Chakraborty. Senior Director, SSA & Co., a global strategic process management consulting firm. For more information, visit ssaandco.com.
Nick Colucci. President and CEO, Publicis ­Healthcare Communications Group, a fully integrated division of Publicis Groupe SA. For more information, visit publicishealthcare.com.
Lisa Davis. VP of Corporate Communications, AstraZeneca US, a major international healthcare ­business engaged in the research, development, ­manufacturing, and marketing of meaningful ­prescription medicines and supplier for healthcare ­services. For more information, visit astrazeneca-us.com.
Todd Everhart, M.D., FACP. Director, Medical Affairs, Americas, Chiltern, a global clinical ­contract research organization with experience conducting and staffing Phase I to Phase IV clinical trials across a broad therapeutic range. For more information, visit chiltern.com.
Bill Hook. VP of Global Strategy, Healthcare Logistics, UPS Supply Chain Solutions, a ­package delivery company and a global provider of supply chain services. For more information, visit ups.com/healthcare.
Ryo Kubota, M.D., Ph.D. Chairman, ­President, and CEO, Acucela Inc., a clinical-stage biotech company focused on ­developing new ­treatments for blinding eye diseases. For more information, visit acucela.com.
Nicholas Landekic. President and CEO, PolyMedix Inc., an emerging biotech company focused on the development of novel drugs and biomaterials for the treatment of ­infectious diseases and acute cardiovascular disorders. For more information, visit ­polymedix.com.
Adelene Perkins. President and Chief ­Business Officer, Infinity Pharmaceuticals Inc., a cancer drug discovery and ­development ­company seeking to discover, develop, and deliver best-in-class medicines for the treatment of cancer and ­related conditions. For more ­information, visit infi.com.
Bob Silvers. Managing Director, SSA & Co., a global operations consulting firm. For more information, visit ssaandco.com.
Tom Steinke. CEO, Minnow Medical Inc., a development-stage company focused on products for the treatment of peripheral artery disease. For more information, visit minnowmedical.com.
Mark Stejbach. VP and Chief ­Commercial Officer, Tengion, a clinical-stage biotechnology company developing ­
neo-organs and tissues derived from a patient’s own (autologous) cells. For more information, visit tengion.com.
Dave Womelsdorf. Americas Advisory Leader, Life Sciences, Ernst & Young, a global provider of assurance, tax, transaction, and advisory services. For more information, visit ey.com.
Steve Wunker. Senior Partner, Innosight, a consultancy that produces a series of market-tested tools and techniques that enable growth through innovation. For more information, visit innosight.com.
Daniel Zurr, Ph.D. CEO and President, Quark Pharmaceuticals Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics. For more ­information, visit quarkpharma.com.

FEEDBACK